CN109475576A - 用于治疗her2阳性转移性乳腺癌的组合物和方法 - Google Patents

用于治疗her2阳性转移性乳腺癌的组合物和方法 Download PDF

Info

Publication number
CN109475576A
CN109475576A CN201680080518.8A CN201680080518A CN109475576A CN 109475576 A CN109475576 A CN 109475576A CN 201680080518 A CN201680080518 A CN 201680080518A CN 109475576 A CN109475576 A CN 109475576A
Authority
CN
China
Prior art keywords
activated
cancer
cells
composition
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680080518.8A
Other languages
English (en)
Chinese (zh)
Inventor
S·拉比扎德
P·宋世宗
H·克林格曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nantes Cell Co
Conkwest Inc
Original Assignee
Nantes Cell Co
Conkwest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantes Cell Co, Conkwest Inc filed Critical Nantes Cell Co
Publication of CN109475576A publication Critical patent/CN109475576A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201680080518.8A 2015-12-09 2016-12-09 用于治疗her2阳性转移性乳腺癌的组合物和方法 Pending CN109475576A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562265382P 2015-12-09 2015-12-09
US62/265,382 2015-12-09
PCT/US2016/066018 WO2017100709A1 (en) 2015-12-09 2016-12-09 Compositions and methods for treatment of her2 positive metastatic breast cancer

Publications (1)

Publication Number Publication Date
CN109475576A true CN109475576A (zh) 2019-03-15

Family

ID=59013368

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680080518.8A Pending CN109475576A (zh) 2015-12-09 2016-12-09 用于治疗her2阳性转移性乳腺癌的组合物和方法

Country Status (8)

Country Link
US (1) US20180360881A1 (enExample)
EP (1) EP3386522A4 (enExample)
JP (1) JP2018537536A (enExample)
KR (1) KR20180123214A (enExample)
CN (1) CN109475576A (enExample)
AU (1) AU2016366677A1 (enExample)
CA (1) CA3007996A1 (enExample)
WO (1) WO2017100709A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112675313A (zh) * 2020-12-28 2021-04-20 烟台大学 连接曲妥珠单抗片段的美登素纳米粒组合物
CN114269377A (zh) * 2019-07-26 2022-04-01 南克维斯特公司 作为用于肿瘤溶解的有效治疗性产品的抗体预加载cd16+nk-92细胞

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4650005A2 (en) * 2016-07-15 2025-11-19 Viracta Subsidiary, Inc. Histone deacetylase inhibitors for use in immunotherapy
JP2020524992A (ja) * 2017-06-22 2020-08-27 ユニバーシティ オブ サザン カリフォルニア キメラ抗原受容体操作ナチュラルキラー細胞を化学療法薬物担体として使用する組み合わせがん療法
WO2019036485A1 (en) * 2017-08-15 2019-02-21 Nantcell, Inc. ASSOCIATIONS OF CÉTUXIMAB AND HIGH AFFINITY NATURAL KILLER CELLS AND ASSOCIATED METHODS
CN110484507B (zh) * 2018-01-31 2023-10-13 温州医科大学 一种靶向肿瘤Her2的新型嵌合抗原受体T细胞的制备技术
IL321548A (en) * 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
KR20210042120A (ko) * 2018-08-06 2021-04-16 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 튜불린 저해제의 조합
US11077143B2 (en) 2018-10-31 2021-08-03 Nantkwest Inc. Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells
EP4178678A1 (en) 2020-07-07 2023-05-17 Cancure, LLC Mic antibodies and binding agents and methods of using the same
CN114807237A (zh) * 2022-05-12 2022-07-29 广东普罗凯融生物医药科技有限公司 一种过表达CD16a的NK细胞的制备方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148926A1 (en) * 2014-03-28 2015-10-01 Regents Of The University Of Minnesota Polypeptides, cells, and methods involving engineered cd16

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1485127T1 (sl) * 2002-02-25 2011-09-30 Elan Pharm Inc Dajanje aktivne snovi za zdravljenje vnetja
EP1836225B1 (en) * 2005-01-06 2011-11-02 Novo Nordisk A/S Kir-binding agents and methods of use thereof
JP5838021B2 (ja) * 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
CN105848662A (zh) * 2013-11-01 2016-08-10 南克维斯特公司 杀肿瘤和抗微生物组合物和方法
CA2980592A1 (en) * 2015-03-27 2016-10-06 Nantkwest, Inc. Nk-92 cells in combination therapy with cancer drugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148926A1 (en) * 2014-03-28 2015-10-01 Regents Of The University Of Minnesota Polypeptides, cells, and methods involving engineered cd16

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JAVIER CORTES等: "Nanoparticle albumin-bound (nabTM)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer", 《EJC SUPPLEMENTS》 *
KURT SCHÖNFELD等: "Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor", 《MOLECULAR THERAPY》 *
LIAT BINYAMIN等: "Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy", 《THE JOURNAL OF IMMUNOLOGY》 *
吴志祥: "《乳腺疾病与乳房美容》", 31 March 2001, 同济大学出版社 *
屈永涛 等: "《耳鼻咽喉口腔恶性肿瘤非手术治疗》", 31 March 2015, 华中科技大学出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269377A (zh) * 2019-07-26 2022-04-01 南克维斯特公司 作为用于肿瘤溶解的有效治疗性产品的抗体预加载cd16+nk-92细胞
CN112675313A (zh) * 2020-12-28 2021-04-20 烟台大学 连接曲妥珠单抗片段的美登素纳米粒组合物

Also Published As

Publication number Publication date
US20180360881A1 (en) 2018-12-20
EP3386522A4 (en) 2019-06-19
CA3007996A1 (en) 2017-06-15
WO2017100709A1 (en) 2017-06-15
EP3386522A1 (en) 2018-10-17
AU2016366677A1 (en) 2018-07-26
KR20180123214A (ko) 2018-11-15
JP2018537536A (ja) 2018-12-20

Similar Documents

Publication Publication Date Title
CN109475576A (zh) 用于治疗her2阳性转移性乳腺癌的组合物和方法
Mroz et al. Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response
CN109789190A (zh) Nant癌症疫苗
CN109069561A (zh) 溶瘤病毒和检查点抑制剂组合疗法
CN106550593A (zh) 用于黑素瘤的抗‑dll3抗体和药物缀合物
CN110545847A (zh) 用于肿瘤的靶向免疫疗法的组合物和方法
CN109475636A (zh) 药物-递送纳米颗粒和耐药癌症的治疗
US20250043023A1 (en) Targeting moiety-drug grafted immune cell compositions and methods of use
Aghajani et al. Current approaches in glioblastoma multiforme immunotherapy
Larkin Investigational RSV vaccine given during pregnancy protects newborns
CN111225673A (zh) 亚德阿霉素组合治疗及方法
US20220105182A1 (en) Radiotherapy improvements
US20230227509A1 (en) Methods and materials for treating cancer
US20240001142A1 (en) Induction by low dose radiation of cancer cell targets for cell-based or small molecule therapy
Aniogo et al. Targeting CEA in metastatic triple negative breast cancer with image-guided radiation followed by Fab-mediated chimeric antigen receptor (CAR) T-cell therapy
AU2018318125A1 (en) Hank cetuximab combinations and methods
Kumar et al. Handbook of Research on Advancements in Cancer Therapeutics
EP3829616A1 (en) Methods and materials for treating cancer
Chaturvedi et al. Immunotherapy for breast cancer
Belver et al. Eric Aniogo¹, Maciej Kujawski¹, Dennis Awuah², Seung E. Cha¹, Ruby Espinosa², Susanta Hui³, Hemendra Ghimire³, Paul J. Yazaki¹, Christine E. Brown, Xiuli Wang²
Jensen et al. CarboCell combinatorial immunotherapy orchestrates curative anticancer immune activation of the tumor microenvironment
Atiq et al. Exploring Novel Neoantigen-Based Treatment Methods for Glioblastoma
Morera-Díaz et al. Anti-VEGF immunotherapy with HEBERSaVax suppresses melanoma growth and metastasis via angiogenesis blockade and enhanced T-cell infiltration
CN120590509A (zh) 分离的特异性结合MHC/Survivin表位复合体的肿瘤特异性TCR及其用途
Weaver Bispecific Antibody Precision Immunotherapy in Non-Hodgkin Lymphoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190315